AmacaThera
- Company typePrivate
- Founded2016
- HeadquartersToronto, Canada
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
AmacaThera firmographics
Firmographics- Name
- AmacaThera
- Legal name
- AmacaThera Inc.
- Website
- https://amacathera.ca
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
AmacaThera industry classification
Industry- Product category
- Biopharmaceutical Drug Delivery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industry
- Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)
Keywords
Where AmacaThera is headquartered
LocationHeadquarters
- HQ city
- Toronto
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
AmacaThera business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others
Revenue model
- Licensing and Milestone Payments: AmacaThera generates revenue through exclusive global licensing agreements with pharmaceutical companies. The company receives upfront payments upon deal signing and additional milestone payments tied to clinical development, regulatory approvals, and commercialization achievements. The Pacira BioSciences agreement includes US$5 million upfront and up to US$225 million in future milestones.
- Co-development Partnerships: Collaborative partnerships where pharma partners fund clinical development activities, with AmacaThera providing its hydrogel platform technology and maintaining ownership of core IP while generating value through partnership structures.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
AmacaThera product offering
Product offeringCore offering
AmacaThera develops and licenses a proprietary injectable hydrogel drug delivery platform (AmacaGel) that integrates hyaluronic acid and methylcellulose for precise, localized, and sustained therapeutic release. Its lead product, AMT-143, is a long-acting non-opioid local anesthetic for post-surgical pain that has completed Phase 1 trials and is being advanced via an exclusive global licensing deal with Pacira BioSciences. The company monetizes its platform by licensing to pharmaceutical partners rather than selling finished products directly.
Product overview
AmacaThera is a clinical-stage biotechnology company offering a proprietary AmacaGel injectable hydrogel drug delivery platform. The platform enables precise, localized, and sustained delivery of therapeutics by integrating hyaluronic acid and methylcellulose. The company's lead product is AMT-143, a long-acting non-opioid analgesic for post-surgical pain, currently in Phase 2 preparation. The AmacaGel platform supports various therapeutic agents including small molecules, biologics, antibodies, peptides, nanoparticles, and cells, with applications spanning post-surgical pain management and oncology.
Differentiator
Problem solved
Functional benefit
Products and services
- AmacaGel Platform Proprietary injectable hydrogel platform combining hyaluronic acid and methylcellulose for tunable, localized, sustained drug delivery. Compatible with small molecules, biologics, enzymes, antibodies, peptides, nanoparticles, and cells. Licensed to pharmaceutical partners for pipeline development across post-surgical pain, oncology, and other indications.
- AMT-143 Long-acting, non-opioid local anesthetic for post-surgical pain management built on the AmacaGel platform. Licensed exclusively to Pacira BioSciences globally; Pacira funds development, manufacturing, and commercialization. Phase 1 completed; Phase 2 planned for 2026.
- Pain (Post-Operative) Fixed Dose Product Pre-filled syringe formulation of a local anesthetic using the AmacaGel hydrogel for sustained post-surgical pain relief. Represents a fixed-dose, ready-to-administer format of the platform's pain indication.
Quantifiable outcome
- Non-opioid alternative for post-surgical pain management reducing reliance on opioids
- +2 more outcomes
Companies that use AmacaThera
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
AmacaThera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AmacaThera partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Pacira BioSciencesflagshipAmacaThera entered an exclusive global licensing agreement with Pacira BioSciences to develop and commercialize AMT-143, a long-acting non-opioid anesthetic for post-operative pain management. The agreement includes a US$5 million upfront payment and potential milestone payments up to US$225 million, validating AmacaThera's tunable hydrogel drug delivery platform. Pacira will fund clinical development, manufacturing, and commercialization, with Phase 2 trials expected to begin in 2026.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
AmacaThera competitors and assessment
Company assessmentDirect peers
- Pacira BioSciences: Pacira is AmacaThera's exclusive global licensee for AMT-143 and a leader in non-opioid, long-acting injectable pain therapeutics (e.g., Exparel). It is directly comparable as a commercial-stage company operating in the same post-surgical pain market AMT-143 targets, and it provides a benchmark for the platform's commercial trajectory.
- Halozyme Therapeutics: Halozyme's ENHANZE drug delivery platform licenses sub-Q delivery technology to major pharma partners (Roche, Pfizer, J&J, etc.) in a model structurally similar to AmacaThera's AmacaGel platform licensing approach. It is the most directly comparable business model in drug delivery platform licensing.
- Heron Therapeutics: Heron develops long-acting, injectable post-surgical pain and oncology support products (e.g., Zynrelef, Sustol). It competes directly with AmacaThera in the post-operative non-opioid pain space and offers a useful commercial-stage benchmark for AMT-143's target indication.
- Innocoll Pharmaceuticals: Innocoll develops biodegradable, collagen-based drug delivery systems for localized and sustained therapeutic release. It is a direct peer in the polymer-based injectable drug delivery platform space and shares AmacaThera's emphasis on tunable, sustained-release formulations.
Emerging players
- Enable Injections: Enable Injections develops subcutaneous drug delivery systems (enFuse) that simplify large-volume, sustained delivery of biologics. It overlaps with AmacaThera's mission of improving patient experience through enhanced injectable delivery technologies, though focused on a different delivery modality.
- InSitu Biologics: InSitu Biologics develops an injectable, sustained-release drug delivery platform (Matrix-Q) targeting post-surgical pain and other localized indications. It overlaps directly with AmacaThera's mechanism and target indication, but is at an earlier commercial stage.
Others
- Crinetics Pharmaceuticals: Crinetics is a clinical-stage biotech that has scaled a platform of peptide therapeutics through major partnerships. It is comparable to AmacaThera as a small-cap clinical-stage biotech leveraging external partnerships to advance proprietary technology platforms.
- Aprea Therapeutics: Aprea is a clinical-stage oncology biotech with a small team and partnered pipeline assets. It serves as a useful comparable for valuation benchmarking of small clinical-stage biotechs operating through partnership/licensing models similar to AmacaThera's.
Broad incumbents
- Bausch + Lomb (Bausch Health): Bausch Health develops sustained-release ocular drug delivery platforms through its Bausch + Lomb unit, including implants and injectable systems. It is a broad incumbent in sustained-release injectable therapeutics that operates across multiple therapeutic areas adjacent to AmacaThera's target spaces.
- Indivior: Indivior commercializes long-acting injectable therapies (e.g., Sublocade) for substance use disorders and is a broader incumbent in long-acting injectable drug delivery. It is comparable in its emphasis on long-acting injectable formulation and commercialization pathways relevant to AmacaThera's AMT-143.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
AmacaThera social profiles
Digital presenceAmacaThera financial estimates
Financial estimateRevenue estimate
Valuation estimate
AmacaThera leadership team
Management profileNumber of profiles
Profiles6 records
AmacaThera funding detail
Funding detailFunding overview
Funding rounds7 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AmacaThera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AmacaThera
What does AmacaThera do?
AmacaThera develops and licenses a proprietary injectable hydrogel drug delivery platform (AmacaGel) that integrates hyaluronic acid and methylcellulose for precise, localized, and sustained therapeutic release. Its lead product, AMT-143, is a long-acting non-opioid local anesthetic for post-surgical pain that has completed Phase 1 trials and is being advanced via an exclusive global licensing deal with Pacira BioSciences. The company monetizes its platform by licensing to pharmaceutical partners rather than selling finished products directly.
Is AmacaThera a public or private company?
AmacaThera is a private company. It is classified as venture growth investor backed and is currently operating.
When was AmacaThera founded?
AmacaThera was founded in 2016. It employs 1 to 10 people.
Where is AmacaThera based?
AmacaThera is headquartered in Toronto, Canada, in the North America region.
How does AmacaThera make money?
Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are co-development Partnerships.
Who are AmacaThera's main competitors?
Direct peers on record are Pacira BioSciences, Halozyme Therapeutics, Heron Therapeutics and Innocoll Pharmaceuticals. Emerging players are Enable Injections and InSitu Biologics. Others are Crinetics Pharmaceuticals and Aprea Therapeutics. Broad incumbents are Bausch + Lomb (Bausch Health) and Indivior.
Does AmacaThera have an API?
No public API is recorded for AmacaThera.
What industry is AmacaThera in?
AmacaThera's product category is Biopharmaceutical Drug Delivery. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 325412 and its SIC code is 2834.